BIOCYTOGEN
21.6.2024 12:51:24 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KleanNara Partners with Rimini Street to Accelerate Digital Transformation25.2.2026 15:00:00 CET | Press release
South Korea’s leading paper manufacturer cuts SAP ECC 6 and Oracle Database maintenance costs with Rimini Support™, freeing up funds and team focus for AI-driven innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced KleanNara has selected Rimini Street to provide support for its SAP ECC 6 and Oracle Database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225123422/en/ KleanNara Partners with Rimini Street to Accelerate Digital Transformation Founded in 1966, KleanNara is one of South Korea’s leading manufacturers of paper and hygiene products. Holding a 25% share of the white cardboard market, the company is known for its commitment to quality, sustainability and innovation, and continues to expand globally with a focus on ESG-driven, eco-friendly products. Breaki
Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence25.2.2026 15:00:00 CET | Press release
Hires Position Firm to Meet Rising Client Demand as Antitrust Enforcement Intensifies Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/ Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners. “Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and
Stonebranch Unveils Latest Release of Universal Data Mover Gateway (UDMG), Advancing Orchestrated B2B MFT25.2.2026 15:00:00 CET | Press release
Secure, enterprise-grade B2B managed file transfer meets orchestration to automate full processes once files are sent or received Stonebranch, a leading provider of service orchestration and automation solutions, today announced the latest release of its Universal Data Mover Gateway (UDMG) — an enterprise-grade managed file transfer (MFT) solution purpose-built for secure, orchestrated B2B data exchange across hybrid landscapes. “In today’s enterprises, file transfer is not a standalone task. It’s the backbone of data pipelines, analytics, and critical business processes,” said Giuseppe Damiani, CEO of Stonebranch. “By orchestrating MFT alongside workload and infrastructure automation, Stonebranch turns file movement into a governed, observable, SLA-driven part of end-to-end enterprise workflows.” Secure, Modern B2B Managed File Transfer UDMG is designed specifically for external B2B data exchanges — where stringent security, regulatory compliance, SLA reliability, and diverse partner
Klarna Reaches 55 Million Monthly App Users as Usage Surges 53% Year Over Year25.2.2026 14:00:00 CET | Press release
Every day 9 million users use Klarna’s app to help them bank and pay Klarna, the global digital bank and flexible payments provider, is seeing a sharp rise in both monthly and daily app usage, as more consumers use the global digital bank’s services as part of their everyday money management. The Klarna app now reaches more than 55 million monthly active users globally, with 9 million people using the app on a daily basis. Daily engagement has increased by approximately 53% compared with last year, highlighting increasingly frequent use of Klarna’s banking, spending and shopping services. Sebastian Siemiatkowski, CEO and co-founder of Klarna: “When people use Klarna every day, it shows we’re delivering on our vision of becoming the global digital bank for the next generation. Consumers are using the app to stay on top of their spending and manage their money, which is exactly how we see Klarna evolving into an everyday money management app people rely on in daily life.” The massive app
Tecnotree Wins in Two Categories at Asian Telecom Awards 202625.2.2026 12:20:00 CET | Press release
Tecnotree, a global leader in AI-native digital business support systems for telecom operators, today announced it has won AI Initiative of the Year – United Arab Emirates and Digital Initiative of the Year – United Arab Emirates at the 2026 Asian Telecom Awards. Winning alongside Singtel, Mobicom, Telkomsel, MyRepublic, Telecom Malaysia, Ooredoo Kuwait, E& and many more reinforces Tecnotree’s industry-leading innovations in AI-powered customer engagement and digital experience platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225387227/en/ Tecnotree Wins in Two Categories at Asian Telecom Awards 2026 The awards recognise Tecnotree’s AI-powered Moments Engagement and Experience Management platform and the MVNE/MVNO CX Catalyst Initiative, two distinct but complementary capabilities that together demonstrate what it means to be a truly AI-native, TM Forum ODA-aligned operator platform. AI Initiative of the Year: Mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom